J Y Zhang1, K Yu2, L J Li1. 1. Lishui Municipal Central Hospital, Lishui, Zhejiang, China. 2. Wenzhou Medical University First Affiliated Hospital, Wenzhou, Zhejiang, China. 172871414@qq.com.
Abstract
PURPOSE: The aim of the present study was to investigate the efficacy and adverse effects of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia (AML) patients of low- and intermediate-risk groups following induction failure. METHODS: A total of 98 AML patients were enrolled. Among these subjects, 47 patients were treated withHCAG chemotherapy, while 51 patients were treated with FLAG chemotherapy. RESULT: The complete remission (CR) and overall remission (OFF) were 24% and 38%, respectively in patients with HCAG induction chemotherapy, while the corresponding percentages were 28% and 42% in subject receiving FLAG chemotherapy. The median survival time of progress-free survival (PFS) was 29.8 (95% CI 23.749-35.851) months in the HCAG group and 30.8 (95% CI 21.728-39.872) months in the FLAG group (P = 0.620). A total of 42 patients in the HCAG group suffered from grade 4 hematological toxicity, while this adverse reaction was noted for all patients who were treated with FLAG chemotherapy (P = 0.023). A total of 19 cases indicated apparent nonhematological toxicity in the HCAG group, while only 40 (78.4%) were noted with these adverse reactions in the FLAG group (P = 0.000). CONCLUSION: The HCAG regimen exhibited a similar effect compared with the FLAG regimen in low- and intermediate-risk groups, although the HCAG regimen significantly decreased the toxicity compared with that noted in the FLAG regimen group.
RCT Entities:
PURPOSE: The aim of the present study was to investigate the efficacy and adverse effects of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia (AML) patients of low- and intermediate-risk groups following induction failure. METHODS: A total of 98 AMLpatients were enrolled. Among these subjects, 47 patients were treated with HCAG chemotherapy, while 51 patients were treated with FLAG chemotherapy. RESULT: The complete remission (CR) and overall remission (OFF) were 24% and 38%, respectively in patients with HCAG induction chemotherapy, while the corresponding percentages were 28% and 42% in subject receiving FLAG chemotherapy. The median survival time of progress-free survival (PFS) was 29.8 (95% CI 23.749-35.851) months in the HCAG group and 30.8 (95% CI 21.728-39.872) months in the FLAG group (P = 0.620). A total of 42 patients in the HCAG group suffered from grade 4 hematological toxicity, while this adverse reaction was noted for all patients who were treated with FLAG chemotherapy (P = 0.023). A total of 19 cases indicated apparent nonhematological toxicity in the HCAG group, while only 40 (78.4%) were noted with these adverse reactions in the FLAG group (P = 0.000). CONCLUSION: The HCAG regimen exhibited a similar effect compared with the FLAG regimen in low- and intermediate-risk groups, although the HCAG regimen significantly decreased the toxicity compared with that noted in the FLAG regimen group.
Authors: Margaret R O'Donnell; Martin S Tallman; Camille N Abboud; Jessica K Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael G Martin; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Eunice S Wang; Kristina M Gregory; Maoko Naganuma Journal: J Natl Compr Canc Netw Date: 2013-09-01 Impact factor: 11.908
Authors: Mike G Martin; Kristan M Augustin; Geoffrey L Uy; John S Welch; Lindsay Hladnik; Sagun Goyal; Divya Tiwari; Ryan S Monahan; Richard M Reichley; Amanda F Cashen; Keith Stockerl-Goldstein; Peter Westervelt; Camille N Abboud; John F Dipersio; Ravi Vij Journal: Am J Hematol Date: 2009-11 Impact factor: 10.047